The intravenous voriconazole (VRC) is formulated by the incorporation of sulfobutylether-β-cyclodextrin (SBECD), which may accumulate to adversely affect renal function. However, the effect of long-term use of intravenous VRC on renal function is unclear. Our retrospective data confirmed that worsening of renal function was significantly associated with cumulative dose of intravenous VRC (≥ 400mg/kg), suggesting that a higher cumulative dose of intravenous VRC was a risk factor for renal dysfunction.
https://ift.tt/2zn3M1j
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.